Global Cosentyx Drug Market Size By Type (Sensoready Pen, Prefilled Syringe), By Application (Hospital, Drugs Store), By Region, And Segment Forecasts, 2023 to 2032

The Global Cosentyx Drug Market was valued at USD 5.9 billion in 2023 and is projected to reach USD 9.7 billion by 2031, growing at a CAGR of 6.6% during the forecast period from 2023 to 2031. The growth of the market is primarily driven by the increasing prevalence of autoimmune diseases such as psoriasis, ankylosing spondylitis, and psoriatic arthritis, alongside expanding therapeutic approvals and geographic outreach. Cosentyx (secukinumab), developed by Novartis, is a leading biologic drug that targets interleukin-17A (IL-17A), showing strong clinical efficacy and sustained long-term outcomes, which are further enhancing its adoption globally.

Drivers:

1. Rising Prevalence of Autoimmune Disorders:

Increasing diagnosis rates of chronic inflammatory conditions like plaque psoriasis and psoriatic arthritis are contributing significantly to market demand for Cosentyx, especially among patients seeking long-term relief with fewer side effects.

2. Expanding Therapeutic Indications:

Cosentyx has received multiple regulatory approvals across different indications and geographies, including approval for use in pediatric patients and non-radiographic axial spondyloarthritis, which is broadening its patient base.

3. Physician and Patient Preference for Biologics:

Owing to the drug’s rapid onset of action and sustained efficacy, Cosentyx is gaining preference among healthcare professionals and patients, particularly those resistant to conventional systemic treatments.

Restraints:

1. Patent Expiry and Biosimilar Threats:

With patent protection expected to phase out in key markets towards the end of the decade, the potential emergence of biosimilars poses a substantial threat to Cosentyx's market share.

2. High Treatment Costs:

The premium pricing of Cosentyx can limit accessibility, especially in developing economies with out-of-pocket healthcare systems or limited insurance coverage.

Opportunity:

1. Emerging Markets and Regional Expansion:

Rapid urbanization, improved healthcare infrastructure, and increasing diagnosis rates in Asia-Pacific and Latin America present untapped growth opportunities for Cosentyx.

2. Real-World Evidence and Long-Term Data Support:

The accumulation of real-world clinical data that reinforces the drug's long-term safety and efficacy may influence prescribing habits and support inclusion in government reimbursement programs.

Market by System Type Insights:

Cosentyx is available as both pre-filled syringe (PFS) and autoinjector (Sensoready® Pen) formulations. Among these, the autoinjector segment accounted for the largest market share in 2023, driven by ease of administration, patient preference for self-injection, and higher compliance rates. As at-home therapies become more popular post-pandemic, this segment is expected to continue leading the market.

Market by End-use Insights:

Hospitals were the dominant end-use segment in 2023, benefiting from structured reimbursement, physician supervision, and biologic infusion protocols. However, the retail pharmacy and homecare segments are projected to grow faster due to increased patient autonomy and advancements in device usability.

Market by Regional Insights:

North America led the global Cosentyx market in 2023, supported by advanced healthcare systems, high biologic drug adoption, and robust insurance coverage. Europe followed closely, benefitting from centralized approval and reimbursement frameworks. However, the Asia-Pacific region is poised for the highest growth during the forecast period, driven by rising disease awareness, expanding pharmaceutical distribution, and market entry into populous countries like China and India.

Competitive Scenario:

Key players influencing the global Cosentyx market include:

Novartis AG (primary manufacturer of Cosentyx)

Eli Lilly and Company

AbbVie Inc.

Amgen Inc.

Johnson & Johnson

While Novartis maintains exclusivity over Cosentyx, competition is intensifying from rival IL-17 and IL-23 inhibitors such as Taltz (Eli Lilly) and Skyrizi (AbbVie). Market players are investing in indication expansion, physician education, and patient support programs to retain and grow market share.

Scope of Work – Global Cosentyx Drug Market

Key Market Developments:

Novartis expanded Cosentyx’s approval in 2023 for treating hidradenitis suppurativa in the U.S., marking a significant portfolio diversification.

In 2024, Novartis launched a patient-centered digital platform supporting at-home Cosentyx injections in Europe.

Regulatory filings in China and Latin America are underway, expected to boost Cosentyx’s footprint in emerging economies by 2026.

Biosimilar tracking programs have been initiated by Novartis to preemptively assess market entry timing and mitigation strategies for post-patent scenarios.

FAQs:

1) What is the current market size of the Global Cosentyx Drug Market?

The market was valued at USD 5.9 billion in 2023.

2) What is the major growth driver of the Global Cosentyx Drug Market?

The increasing prevalence of autoimmune diseases and expanding therapeutic indications are the primary drivers.

3) Which is the largest region during the forecast period in the Global Cosentyx Drug Market?

North America is the largest regional market due to its robust healthcare infrastructure and high biologic adoption.

4) Which segment accounted for the largest market share in the Global Cosentyx Drug Market?

The autoinjector system type segment led the market in 2023.

5) Who are the key market players in the Global Cosentyx Drug Market?

Major players include Novartis AG, Eli Lilly and Company, AbbVie Inc., Amgen Inc., and Johnson & Johnson.